[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. 1989

Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
Department of Pediatrics, Jikei University School of Medicine.

In bacteriological, pharmacokinetic and clinical studies of cefpodoxime proxetil (CPDX-PR, CS-807), the following results were obtained: 1. Antibacteriological activity Antibacteriological activity of R-3746 (Na-salt of cefpodoxime), cefaclor (CCL), cephalexin, cefroxadine (CXD), cefazolin (CEZ), cephalothin (CET) and amoxicillin (AMPC) were studied against clinical isolated bacteria following as: Staphylococcus aureus (resistant or sensitive of methicillin), Escherichia coli (resistant or sensitive to CEZ), Klebsiella pneumoniae (resistant or sensitive to CEZ), Proteus mirabilis and Enterobacter cloacae. Antibacterial activities of CXD and CET, however, were not tested against methicillin resistant S. aureus (MRSA) or CEZ resistant E. coli and K. pneumoniae. R-3746 showed stronger activities than any of the other oral antibiotics against these strains except S. aureus against which it showed slightly less activity than AMPC. Most frequent MIC values of R-3746 to S. aureus, E. coli, K. pneumoniae and P. mirabilis were 1.56, 0.39, less than or equal to 0.10 and less than or equal to 0.10 microgram/ml, respectively. Against isolated strains of MRSA, MICs of R-3746 were higher than 25 micrograms/ml with 23 strains (77%), which were similar to MIC values of CCL and AMPC against these organisms. MIC values of R-3746 against CEZ resistant E. coli and K. pneumoniae were superior to MICs of other antibiotics, and the MIC50 value was 0.20 micrograms/ml. Against many isolated strains of E. cloacae MIC values of R-3746 were relatively high ranging 0.78 to greater than 100 micrograms/ml. MIC50 of R-3746 against E. cloacae was 12.5 micrograms/ml. 2. Absorption and excretion Serum concentration and urinary excretion of CPDX (the active form of CPDX-PR) were studied upon single oral administration of CPDX-PR at 3 mg/kg, 6 mg/kg (dry syrup) or 100 mg (tablet). The peak of serum concentration of CPDX was attained in 1-6 hours 1-4 hours and 2-6 hours after administration of CPDX-PR at the 3 different dosage levels, and they were 0.99-2.99 micrograms/ml, 4.30-7.05 micrograms/ml and 1.65-2.93 micrograms/ml, respectively. At 8 hours after administration, mean concentrations of CPDX for the 3 groups were 0.31, 0.83 and 0.66 micrograms/ml, respectively. As the average AUC's for the 3 groups were 8.16, 25.97 and 10.79 micrograms.hr/ml, respectively. Urinary recovery rates of CPDX for the 3 groups were 20.9-56.2, 28.3-49.7 and 35.1-50.4%, respectively in the first 8 hours after administration.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females

Related Publications

Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
July 1989, The Japanese journal of antibiotics,
Y Toyonaga, and M Koizumi, and H Imai, and M Sugita, and T Takahashi, and Y Fukushima, and M Yamasaki, and M Hori
February 1989, The Japanese journal of antibiotics,
Copied contents to your clipboard!